Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Pharmaceutical Sciences Research Center, Health Institute, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Int J Biol Macromol. 2021 Jan 15;167:1414-1423. doi: 10.1016/j.ijbiomac.2020.11.095. Epub 2020 Nov 14.
In this study, the effect of long-term use drugs of cholesterol-lowering atorvastatin and simvastatin on the activity and molecular structure of pepsin as important gastric enzyme was investigated by various experimental and computational methods. Based on the results obtained from fluorescence experiments, both drugs can bond to pepsin and quench the fluorescence intensity of protein through the static quenching mechanism. Also analysis of the thermodynamic parameters of binding the drugs to pepsin showed that the main forces in the complex formation for both are hydrophobic interactions and van der Waals forces. The effects of the drugs on the enzymatic activity of pepsin were then investigated and results showed that in the presence of both drugs the catalytic activity of the enzyme was significantly increased in lower (0.3-0.6 mM) concentrations however about the atorvastatin, increasing the concentration (0.9 mM) decreased the protease activity of pepsin. Also as a result of the FTIR studies, it was found that binding of the drugs to protein did not significant alteration in the structure of the protein. In order to obtain the atomic details of drug-protein interactions, the computational calculations were performed. The results in good agreement with those obtained from the experimental for interaction; confirm that the drugs both are bind to a cleft near the active site of the protein without any change in the structure of pepsin. Overall from the results obtained in this study, it can be concluded that both simvastatin and atorvastatin can strongly bond to a location close to the active site of pepsin and the binding change the enzymatic activity of protein.
在这项研究中,通过各种实验和计算方法研究了长期使用降脂药物阿托伐他汀和辛伐他汀对重要胃蛋白酶胃蛋白酶的活性和分子结构的影响。基于荧光实验获得的结果,两种药物均可与胃蛋白酶结合,并通过静态猝灭机制猝灭蛋白质的荧光强度。对药物与胃蛋白酶结合的热力学参数的分析也表明,两种药物形成复合物的主要力都是疏水相互作用和范德华力。然后研究了药物对胃蛋白酶酶活性的影响,结果表明,在两种药物存在的情况下,较低浓度(0.3-0.6mM)时,酶的催化活性显著增加,但对于阿托伐他汀,增加浓度(0.9mM)会降低胃蛋白酶的蛋白酶活性。此外,由于 FTIR 研究,发现药物与蛋白质的结合不会导致蛋白质结构的显著改变。为了获得药物-蛋白质相互作用的原子细节,进行了计算计算。结果与实验结果非常吻合;证实两种药物都结合在靠近蛋白质活性部位的裂隙中,而胃蛋白酶的结构没有任何变化。总的来说,从本研究中获得的结果可以得出结论,辛伐他汀和阿托伐他汀都可以与胃蛋白酶的活性部位附近的位置强烈结合,并且结合改变了蛋白质的酶活性。